Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of AZP 531 in patients with type I diabetes mellitus

Trial Profile

Phase II trial of AZP 531 in patients with type I diabetes mellitus

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Livoletide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Dec 2017 According to an Alize Pharma media release, Alize Pharma SAS was acquired by Millendo Therapeutics and subsequently changed its named to Millendo Therapeutics SAS.
    • 01 Oct 2014 New trial record
    • 10 Sep 2014 This trial is expected to be initiated in the last quarter of 2014, according to an Alize Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top